Appeal | Project documents | Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701] | Guidance

Notice of Appeal

Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]

NICE has received an appeal against the Final Draft Guidance on the above technology from the following organisations:

GSK
Myeloma UK

The appeal hearing originally scheduled for Thursday 2 November has been cancelled as the Final Draft Guidance has been withdrawn and the appraisal has been paused.

Please check the topic guidance page for further information and next steps.

GSK : Appeal letter ^{MSWord 494 KB} 20 October 2023
Myeloma UK : Appeal letter ^{MSWord 121 KB} 20 October 2023
GSK : Scrutiny letter ^{MSWord 83 KB} 20 October 2023
Myeloma UK : Scrutiny letter ^{MSWord 76 KB} 20 October 2023
GSK : Response to scrutiny letter ^{MSWord 455 KB} 20 October 2023
GSK : Final scrutiny letter ^{MSWord 70 KB} 20 October 2023
Myeloma UK : Final scrutiny letter ^{MSWord 64 KB} 20 October 2023
NICE TA committee : Written submission ^{MSWord 30 KB} 20 October 2023
NICE Vice Chair : NICE's final response ^{MSWord 45 KB} 20 October 2023